[
    {
        "content": "* Alkermes\u2019 New Drug Application for Investigational Product Designed for Initiation Onto ARISTADA\u00ae accepted for filing by U.S. FDA",
        "date": "11162017",
        "name": "Alkermes plc",
        "news_type": "topStory",
        "symbol": "ALKS",
        "title": "BRIEF-Alkermes\u2019 NDA for ARISTADA accepted for filing by U.S. FDA "
    },
    {
        "content": "* ALKERMES TO INITIATE NEW CLINICAL STUDY EVALUATING ARISTADA\u00ae AND INVEGA SUSTENNA\u00ae FOR THE TREATMENT OF SCHIZOPHRENIA",
        "date": "10262017",
        "name": "Alkermes plc",
        "news_type": "topStory",
        "symbol": "ALKS",
        "title": "BRIEF-ALKERMES INITIATES CLINICAL STUDY EVALUATING ARISTADA  INVEGA SUSTENNA FOR SCHIZOPHRENIA "
    },
    {
        "content": "* \u200dQ3 TOTAL REVENUES INCREASED 21% YEAR-OVER-YEAR TO $217.4 MILLION\u200b",
        "date": "10262017",
        "name": "Alkermes plc",
        "news_type": "normal",
        "symbol": "ALKS",
        "title": "BRIEF-ALKERMES PLC REPORTS \u200dQ3 GAAP LOSS PER SHARE OF $0.24 "
    },
    {
        "content": "* Qtrly revenues increased 12% year-over-year to $218.8 million",
        "date": "07272017",
        "name": "Alkermes plc",
        "news_type": "topStory",
        "symbol": "ALKS",
        "title": "BRIEF-Alkermes qtrly gaap loss per share $0.28 "
    },
    {
        "content": "* Alkermes announces positive preliminary topline results from phase 3 antipsychotic efficacy study of ALKS 3831 for treatment of schizophrenia",
        "date": "06292017",
        "name": "Alkermes plc",
        "news_type": "topStory",
        "symbol": "ALKS",
        "title": "BRIEF-Alkermes announces positive preliminary topline results "
    },
    {
        "content": "* Alkermes announces initiation of study 217 for ALKS 5461 for treatment of major depressive disorder",
        "date": "06122017",
        "name": "Alkermes plc",
        "news_type": "topStory",
        "symbol": "ALKS",
        "title": "BRIEF-Alkermes announces initiation of study 217 for ALKS 5461 "
    },
    {
        "content": "* Alkermes announces initiation of phase 3 study of alks 3831 in young adult patients",
        "date": "06082017",
        "name": "Alkermes plc",
        "news_type": "topStory",
        "symbol": "ALKS",
        "title": "BRIEF-Alkermes initiates phase 3 study of ALKS 3831 in young adult patients "
    },
    {
        "content": "* CEO Richard Pops' 2016 total compensation was $9.6 million versus $12.4 million in 2015 - sec filing Source text (http://bit.ly/2p9SZ48) Further company coverage:",
        "date": "04132017",
        "name": "Alkermes plc",
        "news_type": "topStory",
        "symbol": "ALKS",
        "title": "BRIEF-Alkermes CEO Richard Pops' 2016 total compensation was $9.6 mln vs $12.4 mln in 2015 "
    },
    {
        "content": "* Alkermes plc reports financial results for the year ended dec. 31  2016 and provides financial expectations for 2017",
        "date": "02152017",
        "name": "Alkermes plc",
        "news_type": "topStory",
        "symbol": "ALKS",
        "title": "BRIEF-Alkermes Q4 non-gaap earnings per share $0.15 "
    },
    {
        "content": "* Alkermes inspiration grants(tm) awarded to support people affected by mental health and substance use disorders  Source text for Eikon:  Further company coverage:",
        "date": "11032016",
        "name": "Alkermes plc",
        "news_type": "topStory",
        "symbol": "ALKS",
        "title": "BRIEF-Alkermes inspiration grants awarded to support people affected by mental health and substance use disorders "
    },
    {
        "content": "* Alkermes plc qtrly royalty revenue from Bydureon was $11.6 million  compared to $13.0 million for same period in prior year",
        "date": "11022016",
        "name": "Alkermes plc",
        "news_type": "topStory",
        "symbol": "ALKS",
        "title": "BRIEF-Alkermes Q3 loss per share $0.41 "
    },
    {
        "content": "Oct 21 Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies  including Alkermes  Benchmark Electronics and  Copa Holdings on Friday.               HIGHLIGHTS             * Chesapeake Energy Corp        : Nomura raises to neutral from reduce        * Latam Airlines        : Santander raises to buy from hold       * Proofpoint Inc         : Piper Jaffray raises target price to $90 from $85; overweight                Following is a sum",
        "date": "10212016",
        "name": "Alkermes plc",
        "news_type": "topStory",
        "symbol": "ALKS",
        "title": "U.S. RESEARCH ROUNDUP-Alkermes  Chesapeake Energy Corp  Latam Airlines "
    },
    {
        "content": "Alkermes Plc's experimental depression drug significantly reduced symptoms in patients suffering from major depressive disorder who were not helped by standard treatments in a pivotal late-stage trial  the company said on Thursday  and its shares surged 47 percent.",
        "date": "10202016",
        "name": "Alkermes plc",
        "news_type": "topStory",
        "symbol": "ALKS",
        "title": "Alkermes depression drug succeeds in key trial; shares surge "
    },
    {
        "content": "Oct 20 Alkermes Plc's experimental depression drug significantly reduced symptoms in patients suffering from major depressive disorder who were not helped by standard treatments in a pivotal late-stage trial  the company said on Thursday  and its shares surged 47 percent.",
        "date": "10202016",
        "name": "Alkermes plc",
        "news_type": "normal",
        "symbol": "ALKS",
        "title": "UPDATE 2-Alkermes depression drug succeeds in key trial; shares surge "
    },
    {
        "content": "Oct 20 Alkermes Plc said its lead depression drug met the main goal of a late-stage trial  sending its shares up 48 pct in extended trading.",
        "date": "10202016",
        "name": "Alkermes plc",
        "news_type": "normal",
        "symbol": "ALKS",
        "title": "Alkermes depression drug meets main goal; shares surge "
    },
    {
        "content": "* Alkermes - On Oct. 12  co  certain other subsidiaries of company entered into an amendment to amended and restated credit agreement - SEC filing",
        "date": "10132016",
        "name": "Alkermes plc",
        "news_type": "topStory",
        "symbol": "ALKS",
        "title": "BRIEF-Alkermes  certain subsidiaries enter into amendment to amended  restated credit agreement "
    },
    {
        "content": "* Alkermes announces positive topline results from forward-5 pivotal phase 3 study of alks 5461 for major depressive disorder",
        "date": "10202016",
        "name": "Alkermes plc",
        "news_type": "normal",
        "symbol": "ALKS",
        "title": "BRIEF-Alkermes announces topline results from phase 3 study of Alks 5461 "
    },
    {
        "content": "* Alkermes submits supplemental new drug application to FDA for two month dosing option of Aristada\u007f for treatment of schizophrenia",
        "date": "08082016",
        "name": "Alkermes plc",
        "news_type": "topStory",
        "symbol": "ALKS",
        "title": "BRIEF-Alkermes submits supplemental new drug application to FDA "
    },
    {
        "content": "* Initiation of phase 1 clinical study of immuno-oncology drug candidate ALKS 4230",
        "date": "05252016",
        "name": "Alkermes plc",
        "news_type": "topStory",
        "symbol": "ALKS",
        "title": "BRIEF-Alkermes Plc starts Phase 1 clinical study of immuno-oncology drug candidate "
    },
    {
        "content": "* Alkermes appoints Nancy Snyderman to board of directors  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1 646 223 8780)",
        "date": "05262016",
        "name": "Alkermes plc",
        "news_type": "topStory",
        "symbol": "ALKS",
        "title": "BRIEF-Alkermes appoints Nancy Snyderman to board of directors "
    },
    {
        "content": "* CEO Richard Pops' fy 2015 total compensation was $12.4 million versus $10.4 million in fy 2014 - sec filing",
        "date": "04132016",
        "name": "Alkermes plc",
        "news_type": "topStory",
        "symbol": "ALKS",
        "title": "BRIEF-Alkermes CEO Richard Pops' FY 2015 total compensation was $12.4 million versus $10.4 million in FY 2014 "
    },
    {
        "content": "NEW YORK  Jan 28 Investors who recently shorted Alkermes Plc shares may have had their timing exactly right: They stood to make a nice profit when a setback caused the stock to drop 44 percent.",
        "date": "01282016",
        "name": "Alkermes plc",
        "news_type": "topStory",
        "symbol": "ALKS",
        "title": "Alkermes short bets built up ahead of depression drug setback "
    },
    {
        "content": "Alkermes Plc's depression drug failed in two late-stage studies  underlining the challenges drugmakers face in developing treatments for the condition that affects nearly 17 million Americans.",
        "date": "01212016",
        "name": "Alkermes plc",
        "news_type": "topStory",
        "symbol": "ALKS",
        "title": "Alkermes depression drug fails  shares plunge "
    },
    {
        "content": "* Company loses $3.88 bln in market value   (Adds details  analysts comments; updates shares)",
        "date": "01212016",
        "name": "Alkermes plc",
        "news_type": "normal",
        "symbol": "ALKS",
        "title": "UPDATE 3-Alkermes depression drug fails  shares plunge "
    },
    {
        "content": "Jan 21 Alkermes Plc said its drug for major depressive disorder did not meet the main goal of improving depression symptoms in two late-stage studies.",
        "date": "01212016",
        "name": "Alkermes plc",
        "news_type": "normal",
        "symbol": "ALKS",
        "title": "Alkermes depression drug fails in two late-stage studies "
    },
    {
        "content": "The U.S. Food and Drug Administration on Monday approved Alkermes Plc's longer-acting injectable version of blockbuster schizophrenia pill Abilify  making the treatment available in two doses.",
        "date": "10052015",
        "name": "Alkermes plc",
        "news_type": "topStory",
        "symbol": "ALKS",
        "title": "Alkermes' schizophrenia drug Aristada gets FDA nod "
    },
    {
        "content": "Oct 5 Alkermes PLC said on Monday the U.S. Food and Drug Administration approved its extended-release injectable version of schizophrenia treatment Abilify.",
        "date": "10062015",
        "name": "Alkermes plc",
        "news_type": "topStory",
        "symbol": "ALKS",
        "title": "UPDATE 1-U.S. FDA approves Alkermes' schizophrenia drug Aristada "
    },
    {
        "content": "(Corrects headline to say company will not pursue further development of its drug. The previous headline incorrectly stated that the drug reached main goal) Feb 24 Alkermes Plc :  * Says topline results from a phase 1 clinical study of alks 7106  * Data from the study showed that alks 7106 did not meet the company's pre-specified criteria for advancing into phase 2 clinical trials  * Says will not pursue further development of alks 7106  * Will continue its efforts in developing comp",
        "date": "02242015",
        "name": "Alkermes plc",
        "news_type": "topStory",
        "symbol": "ALKS",
        "title": "CORRECTED-BRIEF-Alkermes says will not pursue further development of ALKS 7106 "
    },
    {
        "content": "(Adds details  stock movement)  (Adds details  share move)",
        "date": "01072015",
        "name": "Alkermes plc",
        "news_type": "topStory",
        "symbol": "ALKS",
        "title": "UPDATE 1-Alkermes schizophrenia drug meets main goal in mid-stage trial "
    },
    {
        "content": "Jan 7 Alkermes Plc said its experimental drug to treat schizophrenia met the main goal in a mid-stage trial.",
        "date": "01072015",
        "name": "Alkermes plc",
        "news_type": "normal",
        "symbol": "ALKS",
        "title": "Alkermes schizophrenia drug meets main goal in mid-stage trial "
    }
]